Consequently, NPM1-mutated, FLT3-ITD-negative AML is classified as a favorable-risk group in the European LeukemiaNet (ELN) guidelines, whereas FLT3-ITD positivity places patients in an intermediate- or adverse-risk category depending on the allelic ratio and co-occurring mutations [159]. The gene discussed is FLT3; the disease is acute myeloid leukemia.